Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2006 Jun 20;24(18):2932-47.
doi: 10.1200/JCO.2006.06.9591. Epub 2006 May 22.

American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006

Practice Guideline

American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006

American Society of Clinical Oncology et al. J Clin Oncol. .

Erratum in

  • J Clin Oncol. 2006 Nov 20;24(33):5341-2

Abstract

Purpose: To update the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology.

Update methodology: The Update Committee completed a review and analysis of data published from 1998 thru February 2006. The literature review focused on published randomized controlled trials, and systematic reviews and meta-analyses of published phase II and phase III randomized controlled trials.

Recommendations: The three-drug combination of a 5-hydroxytryptamine-3 (5-HT(3)) serotonin receptor antagonist, dexamethasone, and aprepitant is recommended before chemotherapy of high emetic risk. For persons receiving chemotherapy of high emetic risk, there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics. These agents should be reserved for patients intolerant of or refractory to 5-HT3 serotonin receptor antagonists, neurokinin-1 receptor antagonists, and dexamethasone. The three-drug combination of a 5-HT3 receptor serotonin antagonist, dexamethasone, and aprepitant is recommended for patients receiving an anthracycline and cyclophosphamide. For patients receiving other chemotherapy of moderate emetic risk, the Update Committee continues to recommend the two-drug combination of a 5-HT3 receptor serotonin antagonist and dexamethasone. In all patients receiving cisplatin and all other agents of high emetic risk, the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis. The Update Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk. CONCLUSION The Update Committee recommends that clinicians administer antiemetics while considering patients' emetic risk categories and other characteristics.

Comment in

  • Controlling emesis: what is it worth?
    Fox SC. Fox SC. J Clin Oncol. 2006 Dec 10;24(35):5617; author reply 5616-7. doi: 10.1200/JCO.2006.08.3238. J Clin Oncol. 2006. PMID: 17158553 No abstract available.

Similar articles

See all similar articles

Cited by 175 articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback